MRMD - MariMed: Q4 Results Reflect Continued Execution On 2021 Transition
- Q4 results reflect continued strong execution on 2021 turnaround.
- Guidance reflects top tier profitability while we believe outstanding acquisitions and investment initiatives will drive share gains and further growth.
- Estimates unchanged.
- Believe limited execution risk ongrowth opportunity warrants creditfrom investors in uncertain times.
- Continue to view Marimed as anunderappreciated operator despite leading execution (and profitability) and the opportunity for transformative growth.
For further details see:
MariMed: Q4 Results Reflect Continued Execution On 2021 Transition